Basildon (UK), 1 December 2020 – Atnahs (“Atnahs”), has acquired the commercial rights for Valium® (Diazepam) in certain territories from Roche. Valium® was launched in 1962 and is mostly used today to treat the symptomatic relief of anxiety and tension, as well as for conscious sedation, premedication and induction of anaesthesia, treatment of excitation states, and treatment of Status Epilepticus.
Since starting out in 2013, Atnahs has grown its product portfolio through both acquisitions of established brands from leading pharma companies, as well as through development of its own branded generics. The acquisition of Valium® represents another acquisition of an established therapy from Roche, and also expands Atnahs’ Neurology & Pain franchise.
“Valium® has been in the market since the 1960s and is an established brand among patients and prescribers. This acquisition is yet another important step in growing our portfolio of high-quality brands and gives us a deeper presence across the globe”, says Dr. Amit Patel, CEO of Atnahs.
Atnahs is a specialty pharmaceutical business, focused on acquiring mature branded medicines out of large cap and specialty pharma companies globally and developing its own niche medicines. Atnahs operates a portfolio of over 20 trusted brands and 2,000 SKUs across 140 markets, with a focus on therapeutic areas such as Cardiovascular, Women’s Health & Endocrinology, Neurology & Pain, and Gastroenterology & Oncology.